Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
FDA Grants Breakthrough Designation to Rare Pediatric and Orphan Drug for Dravet Syndrome
Longboard Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational drug, Bexicaserin. This drug is being developed for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in patients aged two years and older....
Golidocitinib Receives National Approval for Adult Patients with Relapsed T-Cell Lymphoma
Golidocitinib, a first-in-class selective Janus kinase 1 (JAK1) inhibitor, has received approval from the National Medical Products Administration of China for the treatment of adult patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL)....
FDA Approves Verona Pharma's Novel Ohtuvayre™ (ensifentrine) for COPD Maintenance
Ligand Pharmaceuticals has announced that its partner, Verona Pharma has gained approval from the U.S. Food and Drug Administration for Ohtuvayre™ (ensifentrine). This product is the first inhaled treatment with a novel mechanism of action for the maintenance of chronic obstructive pulmonary disease (COPD) in adults in over 20 years....
UC San Diego Health Introduces Novel Melanoma Therapy
UC San Diego Health provided a new immunotherapy treatment for metastatic melanoma. This innovative cellular therapy, derived from tumour-infiltrating lymphocytes (TIL), is the first solid tumour therapy approved by the U.S. Food and Drug Administration (FDA)....
FDA Grants Breakthrough Therapy Designation to Novartis' Scemblix® for First-Line CML
Novartis has announced that the FDA has granted Breakthrough Therapy designation to Scemblix® (asciminib) for treating adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase...
Roche Secures FDA Breakthrough Designation for Lp(a) Cardiovascular Risk Test
Roche announced that its Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation is intended to identify patients who may benefit from innovative Lp(a)-lowering therapies currently in development. ...
U.S. FDA Approves Breakthrough Therapy Designation for Merus Petosemtamab in Cancer Treatment
Merus N.V., a company specializing in innovative cancer treatments with its multispecific antibodies (Biclonics® and Triclonics®), has recently received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for its drug petosemtamab....
FDA Approves Novartis' Lutathera® as Breakthrough Therapy for Pediatric Neuroendocrine Tumors
Novartis has revealed that the U.S. Food and Drug Administration (FDA) has given the green light to Lutathera® for treating children aged 12 and up who have somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including those in the foregut, midgut, and hindgut...
FDA Approves CARVYKTI® First-of-its-Kind CAR-T Therapy for Second-Line Multiple Myeloma
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) has received FDA approval for treating relapsed or refractory multiple myeloma in patients who have tried at least one proteasome inhibitor and one immunomodulatory drug and are no longer benefiting from lenalidomide....
Kura Oncology's Ziftomenib Receives FDA Breakthrough Designation for NPM1-Mutant AML
Kura Oncology, has received Breakthrough Therapy Designation from FDA for their experimental drug, ziftomenib. This designation is for treating patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML)....
